Can GLP-1 Medications Help Women With Polycystic Ovary Syndrome? | Research

The takeaway

GLP-1 receptor agonists show promising results for treating obesity and metabolic dysfunction in PCOS, though long-term safety concerns need further study.

Off-label
GLP-1 RAs are being used for PCOS obesity despite no formal approval for this indication

What the researchers found

GLP-1 receptor agonists produce meaningful weight loss and metabolic improvements in PCOS patients, but serious adverse event concerns warrant further long-term safety investigation.

Why it matters

PCOS affects up to 10% of reproductive-age women, and obesity-driven insulin resistance is central to its pathology — making GLP-1 RAs a logical but understudied treatment option.

The numbers in context

No specific trial results detailed in abstract; reviews clinical trial outcomes involving GLP-1 RAs in PCOS.

How the study worked

Narrative review examining PCOS diagnostic criteria, current treatments, and clinical trial outcomes involving GLP-1 receptor agonists.

Who was studied

Women with polycystic ovary syndrome

What this study cannot tell us

Narrative review; most GLP-1 RA trials in PCOS are small and short-term; long-term reproductive and safety outcomes in this specific population are unknown.

How to read the evidence

Narrative review of clinical trial evidence; individual trials are generally small with limited follow-up periods.

When this study was published

Published in 2025, capturing the current state of GLP-1 RA research in PCOS.

The bigger picture

The off-label use of GLP-1 medications for PCOS reflects a broader trend of these drugs being explored for conditions linked to obesity and insulin resistance, expanding far beyond their original diabetes indication.

Questions still open

Do GLP-1 RAs improve fertility outcomes in PCOS beyond what weight loss alone would achieve?
What are the long-term reproductive safety implications of GLP-1 RA use in women of childbearing age?

Common questions

Can GLP-1 drugs help with PCOS?

Clinical trials show GLP-1 receptor agonists can help PCOS patients lose weight and improve metabolic markers like insulin resistance. However, they are used off-label and long-term safety in this population still needs more research.

Is it safe to use GLP-1 medications with PCOS?

While short-term results are encouraging, this review notes concerns about serious adverse events with long-term GLP-1 RA use. Women with PCOS should discuss the benefits and risks with their doctor, especially regarding reproductive health implications.

Read the original research

The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome.

Cureus, 17(1), e77998

View on PubMed ↗Publisher’s paper ↗

Citation

Rahim, Shaima; Pergolizzi, Joseph. (2025). The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome.. Cureus, 17(1), e77998. https://doi.org/10.7759/cureus.77998